Tumour-suppressor proteins articles within Nature Medicine

Featured

• Article | 13 January 2021

  Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial

  Cabozantinib, an inhibitor of multiple receptor tyrosine kinases, has efficacy in a mouse model of neurofibromatosis type I and has clinical activity in reducing plexiform neurofibroma volume in a phase II trial of patients with NF1.

  • Michael J. Fisher
  • , Chie-Schin Shih
  •  & D. Wade Clapp

• News & Views | 01 January 2010

  Myelodysplasia: battle in the bone marrow

  Innate immune signals and p53 contribute to the 5q– myelodysplastic syndrome, an acquired bone marrow failure disorder (pages 49–58 and 59–66).

  • Yan Liu
  • , Takashi Asai
  •  & Stephen D Nimer